Our data provide a basis for rational design of novel effective combinatorial regimens to overcome resistance and thereby improve the survival of breast cancer patients whose tumors overexpress erbB2 and become resistant to erbB2-targeted therapy. This evidence concerns the gene ERBB2 and breast carcinoma.